Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – Phase IIa
2014-000221-20Phase 2Completed
- Sponsor
- University Hospital Zurich
- Start
- Jun 2014
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of RNS60 in clinically isolated syndrome (CIS) and multiple sclerosis (MS), sponsored by University Hospital Zurich. Primary endpoint: Change in mean number of contrast-enhancing lesions (CELs). Started Jun 2014; status: completed.
02
Drugs
RNS60
03
Conditions
clinically isolated syndrome (CIS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-000221-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000221-20.